Plasma C3c changes in myasthenia gravis patients receiving high-dose intravenous immunoglobulin during crisis.
Fast-migrating C3c, a sensitive index of complement activation, was assayed in the plasma of 2 myasthenia gravis (MG) patients in crisis who received high-dose IV immunoglobulin therapy. Dramatic responses were observed in both patients. Clinical improvement paralleled a decrement in C3c levels, suggesting that regulation of complement activation may be one possible mechanism of IV immunoglobulin treatment in MG.
Kamolvarin
N
N
Department of Medicine and Biochemistry, Faculty of Medicine, Chulalongkorn University Hospital, Bangkok, Thailand.
Hemachudha
T
T
Ongpipattanakul
B
B
Phanuphak
P
P
Viddayakorn
P
P
Sueblinvong
T
T
D000293:Adolescent; D000328:Adult; D003176:Complement C3 / Q000032:analysis*; D005260:Female; D006801:Humans; D007116:Immunization, Passive; D007136:Immunoglobulins / Q000008:administration & dosage*; D007262:Infusions, Intravenous; D008297:Male; D009157:Myasthenia Gravis / Q000097:blood* / Q000628:therapy
D003176:Complement C3; D007136:Immunoglobulins